5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours

Launched by INSTITUTE OF CANCER RESEARCH, UNITED KINGDOM · Oct 4, 2024

Keywords

ClinConnect Summary

The 5G-RUBY clinical trial is testing two experimental medications, avutometinib and defactinib, to see if they are safe and effective for treating certain types of malignant brain tumors, specifically advanced glioblastomas and other aggressive brain cancers. This is a Phase 1 study, meaning it’s one of the first steps in testing a new treatment in people. The trial aims to understand how well these drugs can help shrink tumors while also monitoring any side effects participants may experience. Patients in this trial will take avutometinib twice a week and defactinib twice a day, both given orally.

To be eligible for this trial, participants need to be at least 16 years old and have a confirmed diagnosis of advanced glioblastoma. They should be in relatively stable health, without recent significant complications. Participants will receive careful monitoring throughout the study, with regular check-ups to assess their health and the effectiveness of the treatment. It’s important for patients to give informed consent, meaning they fully understand the trial and agree to participate. If you or a loved one has been diagnosed with one of these brain tumors, this trial may offer a potential treatment option, along with the chance to contribute to important research in this area.

Gender

ALL

Eligibility criteria

• Inclusion Criteria for Phase 1b:
• 1. Patients with histologically confirmed advanced WHO Stage IV glioblastoma (per fourth edition 2016). Per the new 2021 fifth edition of WHO Classification of Tumours of the Central Nervous System, this will include:
• • Glioblastoma, IDH-wildtype Grade 4
• • Astrocytoma, IDH-mutant, Grade 4 (lower Grade 2/3 are not included)
• • Diffuse hemispheric glioma, H3 G34 mutant Grade 4
• • Patients with any other CNS tumours will only be eligible for defined Phase 2 biomarker arms once a Phase 1b GO decision has been met. Specific eligibility criteria for these tumours will be defined following an amendment.
• • 2. Patients for Phase 1 will need to have consented to the Minderoo Precision Brain Tumour Programme and have available whole genome, and transcriptome data available.
• • 3. Patients for the relapsed cohorts will be eligible at first relapse following completion of optimal surgery, and Stupp based adjuvant chemo-radiotherapy (or equivalent). They will need to have measurable disease per RANO or evaluable disease.
• • 4. Patients for the front line minimal residual disease (mrd) cohort will be eligible following completion of optimal surgery and Stupp based adjuvant chemoradiotherapy as long as they meet all other inclusion/exclusion criteria.
• • 5. 16 years or over
• • 6. Life expectancy of at least 12 weeks.
• • 7. World Health Organisation (WHO) performance status of 0-1
• • 8. Neurologically stable (e.g., without a progression of neurological symptoms or requiring escalating doses of systemic steroid therapy within the last week)
• • 9. Written (signed or dated) informed consent and be capable of co-operating with treatment and follow up
• • 10. Haematological and biochemical indices within the ranges shown below. These measurements must be performed within one week prior to the first dose of either IMP
• • Haemoglobin (Hb): ≥ 9.0 g/dL; Absolute neutrophil count: ≥1.5 x 10\^9/L; Platelet count: ≥100 x 10\^9/L; Coagulation: INR \<1.5 and APTT \<1.5x if not anticoagulated, INR stable \> 7 days within intended therapeutic range if anticoagulated; Bilirubin: Within institution normal ranges; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST): \<3 x ULN; Albumin: ≥ 28 g/dL; Creatinine: \<1.5 x ULN; Sodium: ≥130 mmol/L; Potassium, Calcium, Magnesium, phosphate: Within institution normal ranges (replacement is permitted); Urinary protein: \< 1+ on dipstick.
• • 11. Female patients with reproductive potential must have a negative serum pregnancy test within 14 days prior to start of trial.
• • 12. Men and women of childbearing potential must agree to comply with the use of a highly effective method of contraception to avoid impregnating a partner or becoming pregnant, respectively, during the study, and for at least 150 days after the last dose of either investigational drug.
• Exclusion Criteria for Phase 1b:
• 1. Receipt of treatment before the first dose of study drug (Cycle 1 Day 1) within an interval shorter than the following, as applicable:
• • Cytotoxic chemotherapy during the prior 2 weeks or 6 weeks for nitrosoureas
• • Bevacizumab during the prior 6 weeks
• • Five half-lives of any small molecule investigational or licensed medicinal product.
• • 2. Prior immune checkpoint inhibitor therapy or vaccine therapy is not permitted. Prior use of any other immune-modulatory investigational agent must be discussed with sponsor team and CI. Prior use of BRAF or MEK inhibitors is not permitted.
• • 3. Ongoing Grade 2 or greater toxicities from pre-existing conditions or from previous treatments.
• • 4. Patients with carcinomatous meningitis, leptomeningeal spread of tumour, spread of tumour to the brain stem or spinal cord.
• • 5. Has evidence of recent intratumoural or peritumoural haemorrhage on baseline MRI. Patients with radiological findings that are stable on at least 2 consecutive MRI scans at least 3 weeks apart will be eligible.
• • 6. History of clinically relevant bleeding disorders, including significant GI bleeding within last 6 months.
• • 7. History of arterial thromboembolism.
• • 8. Recent (within 3 months) deep vein thrombosis or pulmonary embolism or another significant thromboembolism. Venous port of catheter thrombosis or superficial thrombosis are not considered significant. Patients with prior thrombosis (\> 3 months ago) on stable anticoagulation are permitted to be enrolled. Patients on Warfarin will need to be converted onto low-molecular weight-based heparin therapy.
• 9. History of clinically significant cardiac disorders:
• • Myocardial infarction, or New York Heart Association Class II to IV congestive heart failure, within 6 months of the first dose of study drug
• • Concurrent and clinically significant abnormalities on ECG at Screening, including a corrected QT interval (QTcF \>460ms).
• • 10. History of malabsorption syndrome or other conditions that may interfere with enteral absorption. Patients with a history of or active inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis). Patients with acute or chronic pancreatitis. History of gastrointestinal perforation or fistulae. Patients with known Gilbert's syndrome will be excluded from this study.
• 11. Concurrent ocular disorders:
• • 1. Patients with history of glaucoma, history of retinal vein occlusion (RVO), predisposing factors for RVO, including uncontrolled hypertension, uncontrolled diabetes
• • 2. Patient with history of retinal pathology or evidence of visible retinal pathology that is considered a risk factor for RVO, intraocular pressure \> 21 mm Hg as measured by tonometry, or other significant ocular pathology, such as anatomical abnormalities that increase the risk for RVO.
• • 3. Patients with a history of corneal erosion (instability of corneal epithelium), corneal degeneration, active or recurrent keratitis, and other forms of serious ocular surface inflammatory conditions.
• • 12. Has urine protein \> 1g/24 hours. Participants with \>1+ on urine dipstick testing will undergo 24-hour urine collection for quantitative assessment of proteinuria.
• • 13. Has significant lung disease including pneumonitis, interstitial lung disease, idiopathic pulmonary fibrosis, cystic fibrosis, active tuberculosis, or history of opportunistic infections (including PCP or CMV pneumonia).
• • 14. Known to be serologically positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV).
• • 15. Steroid requirement for neurological symptom control of \> 3mg Dexamethasone per day (patients will allowed to enrol if they have been on a stable dose of steroids of equivalent or less than 3mg Dexamethasone for at least 5 days prior to Day 1 of Cycle 1).
• • 16. Has received a live vaccine within 30 days of planned start of study therapy. Note: inactive vaccines including COVID vaccines are allowed prior to 1 week of Day 1 of Cycle 1).
• • 17. Current active concurrent malignancy. Cancer survivors who have undergone potentially curative therapy for a prior malignancy, have no evidence of that disease recurrence for three years or more and are deemed at negligible risk of recurrence will be eligible.
• • 18. Is a participant or plans to participate on another interventional clinical trial while taking part in this Phase 1 study. Participation in an observational trial would be acceptable.
• 19. Exposure to medications (with or without prescriptions), supplements, herbal remedies, or foods with potential for drug-drug interactions with study interventions within 14 days prior to the first dose of study intervention and during the course of therapy, including:
• • 1. Strong CYP3A4 inhibitors or inducers, due to potential drug-drug interactions with both avutometinib and defactinib.
• • 2. Strong CYP2C9 inhibitors or inducers, due to potential drug-drug interactions with defactinib. Not applicable if and when patients randomized to avutometinib monotherapy.
• • 3. Strong P-glycoprotein (P-gp) inhibitors or inducers, due to potential drug-drug interactions with both avutometinib and defactinib.
• • 4. Strong breast cancer resistance protein (BCRP) inhibitors or inducers, due to potential drug-drug interactions with avutometinib.
• • 20. Major surgery within 4 weeks (excluding placement of vascular access), minor surgery within 2 weeks, or palliative radiotherapy within 1 week of the first dose of defactinib.
• • 21. Any other condition which in the investigator's opinion would not make the patient a good candidate for the clinical trial.